Amifostine (intravenous) vs Amifostine (subcutaneous)
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) led to lower xerostomia (grade >= 2, 0-4 scale) compared with amifostine (subcutaneous); GRADE not reported.
2 findings from 1 review
- Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes12 months postRTRR 0.61 [0.42, 0.88]1 study · 127 participantsGRADE not reported
- Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomesUp to and including 3 months postRTRR 1.03 [0.76, 1.40]1 study · 263 participantsGRADE not reported